Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
Leukemia|January 27, 2025
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, et al.
Leukemia & Lymphoma|September 1, 2011
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaDavid Claxton, Harry P Erba, Stefan Faderl, et al.
Clinical Trials (London, England)|January 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trialsAnna Moseley, Michael LeBlanc, Boris Freidlin, et al.
Leukemia|May 3, 2016
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemiaM Othus, B L Wood, D L Stirewalt, et al.
Leukemia|June 3, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203Michelle Y Zhang, Megan Othus, Kerry McMillen, et al.
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Investigational New Drugs|February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Harry P Erba, Hamid Sayar, Mark Juckett, et al.
Plos One|February 16, 2017
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Plos One|December 2, 2016
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
Leukemia|January 27, 2025
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, et al.
Leukemia & Lymphoma|September 1, 2011
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaDavid Claxton, Harry P Erba, Stefan Faderl, et al.
Clinical Trials (London, England)|January 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trialsAnna Moseley, Michael LeBlanc, Boris Freidlin, et al.
Leukemia|May 3, 2016
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemiaM Othus, B L Wood, D L Stirewalt, et al.
Leukemia|June 3, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203Michelle Y Zhang, Megan Othus, Kerry McMillen, et al.
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Investigational New Drugs|February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Harry P Erba, Hamid Sayar, Mark Juckett, et al.
Plos One|February 16, 2017
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Plos One|December 2, 2016
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaKentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, et al.
Pageof 17